Dr. Tang serves as CEO of Shenox, which he co-founded in 2015. He also serves as chairman of GDB, which he founded in 2017 .

Dr. Tang is an expert in PK/PD and earned his PhD in Pharmaceutical sciences from the University of Arizona. He holds a bachelor degree in Microbiology from Fudan University. 

Dr. Tang worked in Wyeth, Schering Plough, Bristol-Myers Squibb for over than 10 years as a PK/PD expert. As a core member of the project team, he was responsible for drug metabolic dynamics and pharmacological research and development. His work covered a wide spectrum of activities from project initiation to post-clinical development and registration, in diverse therapeutic areas such as  diabetes, oncology, infections, and neuroscience.He was responsible for human pharmacokinetic/dose prediction and early clinical pharmacology in most project pharmacological assessments.

 A predictive clinical pharmacokinetic model (Tang's Coefficients; FCIM) was created that is widely used by the pharmaceutical academic and industrial communities. These models are important tools for evaluating the drug-made nature of new drugs and clinical pharmacological research.

He specializes in FDA communication, specializing in quantitative pharmacology (conversion, clinical), designing optimized and efficient 505b(2) paths.